Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 4,200 shares of the firm’s stock in a transaction on Thursday, October 6th. The shares were acquired at an average price of $10.53 per share, with a total value of $44,226.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $32,316,054.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, October 4th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were purchased at an average cost of $10.57 per share, for a total transaction of $38,052.00.
  • On Friday, September 30th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.54 per share, for a total transaction of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were purchased at an average cost of $10.67 per share, for a total transaction of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were purchased at an average cost of $11.01 per share, for a total transaction of $59,454.00.
  • On Tuesday, September 27th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $11.16 per share, for a total transaction of $20,088.00.
  • On Monday, September 26th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $11.04 per share, for a total transaction of $19,872.00.
  • On Friday, September 23rd, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.95 per share, for a total transaction of $19,710.00.
  • On Thursday, September 22nd, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.63 per share, for a total transaction of $19,134.00.
  • On Wednesday, September 21st, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.46 per share, for a total transaction of $18,828.00.
  • On Tuesday, September 20th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were purchased at an average cost of $10.36 per share, for a total transaction of $18,648.00.

Shares of Opko Health Inc. (NYSE:OPK) traded down 6.9540% during mid-day trading on Friday, hitting $9.7047. The stock had a trading volume of 4,628,910 shares. Opko Health Inc. has a 1-year low of $7.12 and a 1-year high of $11.85. The company has a market capitalization of $5.34 billion and a P/E ratio of 40.6054. The stock’s 50-day moving average price is $10.06 and its 200 day moving average price is $10.13.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The business’s quarterly revenue was up 742.2% compared to the same quarter last year. On average, analysts predict that Opko Health Inc. will post ($0.05) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bridger Management LLC purchased a new position in shares of Opko Health during the first quarter worth approximately $13,863,000. Amici Capital LLC purchased a new position in shares of Opko Health during the first quarter worth approximately $842,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Opko Health during the first quarter worth approximately $141,000. LGL Partners LLC purchased a new position in shares of Opko Health during the first quarter worth approximately $556,000. Finally, Geode Capital Management LLC raised its position in shares of Opko Health by 6.6% in the first quarter. Geode Capital Management LLC now owns 1,923,455 shares of the company’s stock worth $19,984,000 after buying an additional 118,512 shares in the last quarter.

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. set a $14.00 price target on shares of Opko Health and gave the company a “buy” rating in a report on Tuesday, August 9th. Standpoint Research upped their price target on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, June 21st. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a report on Thursday, June 16th. Jefferies Group reaffirmed a “hold” rating and issued a $10.00 price target (down from $11.00) on shares of Opko Health in a report on Friday, June 17th. Finally, Deutsche Bank AG cut their price target on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a report on Thursday, June 16th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $13.20.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.